Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Seroquel data show significant improvement in compliance and cognition in schizophrenia

24.05.2005


Patients with schizophrenia who are treated with the atypical antipsychotic SEROQUEL (Quetiapine) show significantly superior rates of treatment compliance compared to patients treated with other atypical and typical antipsychotics, according to new data presented today at the American Psychiatry Association (APA) meeting in Atlanta, USA. Additional data presented today also showed improved cognitive functioning for patients with schizophrenia who are treated with SEROQUEL.



The compliance study is one of the few to compare both atypical antipsychotics with each other as well as with typical antipsychotics in schizophrenia. The findings show SEROQUEL to have the highest compliance rate of both typicals and atypicals, which was significantly (P<0.05) greater than that of risperidone (6% greater) and olanzapine (4% greater). These are welcome results in a patient environment where up to 50% of patients fail to comply with their prescribed medication, leading to an increased risk of relapse. This can result in the need for rehospitalisation and potential for high socioeconomic costs.

"Compliance with medication is fundamental to a successful treatment outcome in schizophrenia. However, all too often patients have to struggle with medications that cause distressing side effects such as extrapyramidal symptoms (EPS), increased prolactin levels leading to galactorroeha and sexual dysfunction, which makes complying with treatment a challenge many patients find too difficult to overcome" commented Dr Michael Riedel from the Munich University Hospital, Germany. "It is critical therefore that medications are not only effective in treating symptoms but are also well tolerated, which is where atypicals such as SEROQUEL are able to offer patients an improved outcome."


Cognitive Function

Two other studies presented at this year’s APA meeting compared the cognitive benefits of SEROQUEL and risperidone in patients with schizophrenia, demonstrating improvements in cognitive function among Seroquel-treated patients:

  • In a randomized, double-blind study of 44 patients, both SEROQUEL and risperidone improved cognition in patients with schizophrenia over a 6-week period. However, SEROQUEL (at a mean dose of 566.7 mg/day) produced significantly greater improvements in working and verbal memory than risperidone (p<0.01 and p<0.05 vs risperidone, respectively), with a significantly lower incidence of EPS, a highly distressing treatment-induced side effect
  • In an 8-week, double-blind, flexible-dose, parallel study randomizing 673 patients with schizophrenia, cognitive benefits of SEROQUEL (mean modal dose of 530 mg/day) and risperidone were compared. Both medications were associated with overall improvements in cognitive functioning (p<0.01) versus baseline.

"It is encouraging to see that SEROQUEL appears to be at least as effective as risperidone in improving cognitive function while also demonstrating a superior side effect profile in terms of extrapyramidal symptoms" continued Dr. Riedel. "Cognitive impairment is a serious symptom but one which is sometimes perceived as less important than some other symptoms of schizophrenia, such as hallucinations. However, recent studies have found that cognitive function is directly related to many areas of social interaction, and can limit an individual from being able to benefit fully from rehabilitation programmes. That is why treating these symptoms effectively is so important."

SEROQUEL has been licensed for the treatment of schizophrenia since 1997 and is available in 82 countries for the treatment of this condition. Results of recent studies show that 600mg/day is an efficacious SEROQUEL dose in patients with schizophrenia. SEROQUEL is also licensed in 63 countries for the treatment of mania associated with bipolar disorder, including the US, Canada and several European countries. To date, over 8 million people have been treated with SEROQUEL worldwide.

Sarah Fraser | EurekAlert!
Further information:
http://www.shirehealth.com

More articles from Health and Medicine:

nachricht Vanishing capillaries
23.03.2017 | Technische Universität München

nachricht How prenatal maternal infections may affect genetic factors in Autism spectrum disorder
22.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Vanishing capillaries

23.03.2017 | Health and Medicine

Nanomagnetism in X-ray Light

23.03.2017 | Physics and Astronomy

Pulverizing electronic waste is green, clean -- and cold

22.03.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>